A novel cellular homing/chemokine delivery system was developed, in which electrospun polydioxanone (PDO) scaffolds infused with Monocyte Chemotactic Protein-1 (MCP-1) were fabricated and examined for their potential to influence macrophage infiltration/adherence and for their potential to provide extended chemokine release. Over the course of 120 hours, MCP-1 released into supernatant peaked at 24 hours and was detectable by enzymelinked immunosorbent assay (ELISA) when added to PDO solutions prior to electrospinning at 3000 ng/ml. PDO/MCP-1 hybrids were characterized for biological activity using a test tube ELISA procedure assessing macrophage adherence/infiltration of scaffolds. Results demonstrated an increasing doseresponsive trend with increasing MCP-1 concentration. These initial investigations suggest such hybrid materials have significant potential for use in and improvement of in situ tissue regeneration applications by acting as cellular homing devices.
INTRODUCTION
(PEVA) and poly(lactic acid) (PLA) [1] . Results indicated that electrospun PEVA and 50/50 PEVA/PLA demonstrated prolonged release of tetracycline over five days, obtaining larger percent release levels than other materials tested. In contrast, films of the same materials did not demonstrate continued release, plateauing within 24 hours. Following that published success, others have used electrospun fibers as a vehicle for controlled release of other antibiotics [2, 3] , pain relievers [4, 5] , and proteins [6] [7] [8] [9] . This suggests that it may be possible, with the incorporation of an appropriate chemokine, to use these electrospun devices as cellular homing scaffolds that could promote improved angiogenesis and remodeling of bioresorbable scaffolds. The incorporation of a chemokine (RANTES) into biodegradable nanoparticles has been previously reported by Ham et al. [10] , however no current published research examines incorporating chemokines into biodegradable electrospun scaffolds and their potential as cellular homing devices.
Successful in situ regeneration of bioresorbable vascular prosthetics has been reported previously. Using a rabbit implantation model, Greisler et al. utilized polydioxanone (PDO) vascular prosthetics and reported successful in situ regeneration up to 12 months post-implantation. Specifically, explants demonstrated an enhanced endothelial cell lining and mechanical properties matching native artery at two weeks and twelve months post-implantation, respectively [11] . Following these and other studies, the authors suggested that the enhanced endothelial lining was due to transinterstitial migration of capillaries, while the overall healing was initiated largely by macrophage activation due to interaction with the polymer.
Macrophages are specialized phagocytes, and they are the dominant type of cells that respond actively and rapidly to implanted biomaterials [12] . Although macrophages are primarily responsible for phagocytosis of foreign debris, they also play a significant role in tissue regeneration and angiogenesis, and any potential regeneration will likely depend greatly on macrophage secretory activity. As suggested by Greisler et al., the macrophage may play a central role in the success or potential failure of acellular, bioresorbable vascular prosthetics. In addition, others have suggested that the number of macrophages present during tissue regeneration directly correlates with the degree of angiogenesis [13, 14] . Thus, it may be highly desirable to promote macrophage infiltration and interaction with bioresorbable prosthetics in order to improve in situ regeneration. Potentially, this can be achieved by infusing biomaterials with one or more chemokines that promote macrophage chemotaxis.
The premise of the in situ approach to tissue engineering is that the body, when appropriately stimulated, can remodel an implanted tissueengineered device to produce new functional tissues and/or organs. A number of chemokines, including MCP-1 and RANTES, have been identified as important to the vascular remodeling process [15] . Of these, MCP-1 has received increasing attention in the biomedical community due to its potent chemoattractant effects on mononuclear phagocytes [16] and for its role in tumor vasculogenesis [17] .
MCP-1 is more potent than many other chemokines, including RANTES due to its high affinity for its own receptor (CCR2), in addition to its affinity for other CC chemokine receptors (such as the RANTES receptor, CCR5) [16, 18] . One of the primary roles of MCP-1 is the recruitment of monocytes and macrophages to injured tissue, and because these cells are the primary cells responsible for promoting angiogenesis, this chemokine is a critical part of the tissue regeneration process. MCP-1 has also been shown to be a significant chemoattractant for cells other than monocytes and macrophages, including NK cells, CD4+ and CD8+ T-cells [19, 20] . Recent reports have also shown that MCP-1 is chemotactic for vascular smooth muscle cells [21] and mesenchymal stem cells [22] .
With regard to angiogenesis, MCP-1 has been shown to increase vascular endothelial growth factor (VEGF) production in human umbilical vein endothelial cells [17] . Also, vascular endothelial cells have been shown to express CCR2, and these cells also demonstrate chemotaxis and formation of tubes in vitro in response to MCP-1 [23] . Given this wealth of evidence, MCP-1 appears to be an ideal candidate for incorporation into tissue regeneration scaffolds in order to improve scaffold remodeling and de novo tissue formation. In these preliminary studies, MCP-1 was incorporated as a model chemokine into PDO solutions prior to electrospinning in order to create cellular homing scaffolds with the potential to stimulate in situ angiogenesis and tissue regeneration, and the resulting delivery systems were evaluated for both their release of MCP-1 over time and for their biological activity in vitro.
MATERIALS AND METHODS

Adherent Splenic Macrophage Isolation from Murine Spleen Cells
All animal work was conducted under a protocol approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee in an AAALAC-accredited facility. B6C3F1 mice were euthanized by CO 2 inhalation followed by gentle cervical dislocation.
Spleens were collected aseptically and gently mashed between frosted ends of two sterile microscope slides to prepare single-cell splenocyte suspensions.
Splenocytes were resuspended in Roswell Park Memorial Institute (RPMI) 1640 media supplemented with 10% fetal bovine serum (FBS), 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mM Lglutamine, 5% sodium bicarbonate (7.5% stock solution), 50 g/ml gentamicin, and 10 M 2-mercaptoethanol (2-ME) (complete media) prior to pooling of all cells and adjusting of cell concentrations. Adherent splenic macrophages were isolated from the pooled splenocytes by incubating splenocytes in 75-cm 2 flasks for 3 hours at 37C and 5% CO 2 . Following incubation, non-adherent cells were poured off, and plates were gently washed with warm (37C) PBS and then incubated at room temperature with cold 5 mM ethylenediamine-tetraacetic acid (EDTA) in PBS for 45 minutes on an orbital shaker.
Finally, cells were washed, resuspended in complete RPMI, and adjusted to the desired cell concentration prior to use.
Preparation of Electrospun Polydioxanone Scaffolds
Incorporated with Monocyte Chemotactic Protein-1 (MCP-1) MCP-1 (Antigenix America Inc, Huntington Station, NY, USA) was prepared in sterile water with 0.1% bovine serum albumin at 30g/ml and stored at -20C until use. Polydioxanone (PDO) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP; TCI America) at 100 mg/ml and was subsequently blended with MCP-1 at four different concentrations (3, 30, 300, or 3000 ng/ml) prior to electrospinning onto a rectangular mandrel (7.5 cm  1 cm  0.5 cm). PDO was also electrospun without MCP-1 from the same stock PDO solution. Two milliliters of each polymer solution were loaded into 3-ml BectonDickenson syringes fitted with 18-gauge blunt-tipped needles and dispensed at 6 ml/hr using a KD Scientific syringe pump. During electrospinning, a fixed voltage of +22 kV was applied to the needle by a Spellman CZE1000R high voltage power supply (Spellman High Voltage Electronics Corp., Hauppauge, NY, USA), while a fixed voltage of -10 kV was applied to a target 15 cm behind the grounded mandrel using a second CZE1000R. Mandrel rotation speed was maintained at 500 RPM, while mandrel translation was maintained at 2 cm/s over a distance of  3.75 cm during electrospinning in order to ensure a random, even fiber distribution. The air gap distance was maintained at 28 cm during electrospinning. Scaffolds were stored at -20C until use. Prior to use, circular punches of material (varying diameters, depending on assay) were disinfected for 10 minutes in ethanol followed by three successive 10-minute rinses in sterile PBS.
Macrophage Adherence and Infiltration of
Electrospun PDO Scaffolds Incorporated with MCP-1 10-mm diameter circular punches of PDO or PDO/MCP-1 scaffolds were cut in half, disinfected with ethanol and rinsed three times in sterile PBS. Following culture with splenic adherent macrophages (5x10 6 /ml, 0.75 ml) overnight in BD Falcon 12x75 mm polystyrene tubes, material samples were removed from the tubes, rinsed five times each in five different tubes containing PBS, and placed into fresh Falcon tubes. This rinsing procedure was followed by the addition of 1 ml per tube of a 1:500 dilution of fluorescein isothiocyanate (FITC)-conjugated anti-mouse MAC3 antibody (eBioscience, San Diego, CA, USA). Following a one-hour incubation in the dark at room temperature, the rinsing procedure was repeated, and materials were placed into fresh Falcon tubes, followed by the addition of 1 ml per tube of a 1:500 dilution of sheep anti-FITC antibody conjugated with horseradish peroxidase (HRP; Southern Biotech, Birmingham, AL, USA). After incubation in the dark for 1 hour at room temperature, the rinsing procedure was performed, and materials were again placed into fresh Falcon tubes, followed by the addition of 200 l 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The addition of 2 N H 2 SO 4 after 10 minutes stopped the reaction, and 100 l from each test tube was placed into wells of a 96-well Immulon-2 plate. The optical density of each sample was determined at 450 nm using a THERMO max microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA). Results were obtained using Softmax version 2.32 (Molecular Devices Corp., Sunnyvale, CA, USA) and reported in terms of the mean optical density (O.D.) for each group.
Enzyme-Linked Immunosorbent Assay of TimeDependent MCP-1 Release from Electrospun
Polydioxanone-MCP-1 Hybrid Structures 6-mm diameter circular punches of PDO or PDO/MCP-1 scaffolds (3, 30, 300, and 3000 ng/ml) were disinfected with ethanol and rinsed three times in sterile PBS prior to being incubated for 24, 48, 72, 96, and 120 hours in 96-well plates in phenol-red free RPMI 1640 supplemented with 15 mM HEPES, 2 mM L-glutamine, 1% 100  MEM non-essential amino acids (Gibco Product # 11140), 1% 100  MEM vitamins (Gibco #11120), and 0.05% bovine serum albumin. Following incubation, aliquots of supernatant were collected and stored at -70C until needed for use. A release profile characterizing timedependent MCP-1 release from PDO/MCP-1 hybrid scaffolds was determined via enzyme-linked immunosorbent assay (ELISA) in order to quantify the amount of MCP-1 in supernatant cultures, using a matched pairs mouse MCP-1 ELISA kit (BD Biosciences) according to kit instructions. Briefly, plates were coated with anti-mouse MCP-1 at the recommended dilution overnight at 4 C. Plates were washed three times with PBS/Tween-20, blocked for one hour with 10% fetal bovine serum in PBS ("assay Plates were incubated at room temperature for 2 hours followed by five washes with PBS/Tween-20 and the subsequent addition of antimouse MCP-1 antibody conjugated with HRP. After a one-hour incubation at room temperature, plates were washed seven times with PBS/Tween-20 followed by the addition of TMB substrate. Plates were incubated in the dark for 30 minutes and absorbance at 450 nm was determined using a SpectraMax Plus 384 (Molecular Devices Corp., Sunnyvale, CA).
Results were obtained using SoftMax Pro version 5.2 (Molecular Devices Corp., Sunnyvale, CA) by comparison with the linear portion of the standard curve generated during analysis. Results were reported as the concentration of MCP-1 present in each sample.
Statistical Analysis
In all experiments, adherent splenic macrophages were pooled and four material samples from each experimental group were used, unless otherwise indicated.
Statistical analysis of all data was performed using the JMP TM 5.0 statistical software package (SAS Institute, Cary, NC, USA) by first using Bartlett's test for homogeneity of variances, followed by a one-way analysis of variance (ANOVA). In all experiments, the control group was the 0 ng/ml treatment group. To examine statistically significant differences between control and treatment groups, Dunnett's test was employed. To examine pair-wise differences between treatment groups, the Tukey-Kramer test was utilized. In all evaluations, p < 0.05 indicated statistically significant differences.
RESULTS
Effects of PDO/MCP-1 Hybrid Scaffolds on Macrophage Adherence and Infiltration
In order to evaluate both the presence of MCP-1 in PDO/MCP-1 electrospun hybrid scaffolds and the biological activity of these structures, electrospun PDO and electrospun PDO/MCP-1 hybrid materials were cultured overnight with splenic adherent macrophages and then evaluated for the presence of macrophages on and/or within the structures using a test tube ELISA procedure. Results of a preliminary experiment to determine if biologically active MCP-1 was indeed present in the electrospun hybrids are shown in Figure 1A . MCP-1 incorporated at 3000 ng/ml prior to electrospinning produced a statistically significant increase (179%) in macrophage adherence/infiltration over 0 ng/ml experimental control cultures (PDO scaffolds devoid of MCP-1 but cultured with cells). Background (BG) cultures consisted of PDO cultured in media without cells and were utilized to control for incomplete rinsing/removal of unbound antibody from materials. Experimental control cultures (0 ng/ml) were not statistically different from background control cultures. Results for this experiment are given as the optical density (O.D.) at 450 nm, as there is no standard for this assay. Figure 1B depicts results of an experiment to determine a potential dose-responsive relationship between MCP-1 concentration and macrophage adherence/infiltration. Percent of controls for each of the groups were: 102.3% (BG), 91.8% (3 ng/ml), 100% (30 ng/ml), 141.7% (300 ng/ml), and 170.8% (3000 ng/ml).
Results demonstrated a doseresponsive increase in macrophage adherence/infiltration with increasing MCP-1 concentration, reaching the level of statistical significance at 3000 ng/ml.
Instead of subtracting out BG values, they are shown for both experiments. In both assays, the BG was not different from the experimental control cultures (0 ng/ml). However, there was a difference in the magnitude of the response between experiments due to differences in washing away of non-specific bound antibody. (5 10 6 /ml, 0.75 ml). Samples were stained with hematoxylin and eosin (H&E) and imaged at 40   magnification using a Nikon Eclipse TE300 equipped with a Nikon DXM 1200 digital camera. Figure 2A depicts the PDO scaffold following culture without cells, while Figure  2B depicts pure PDO cultured with cells and demonstrates very few cells adhered to scaffolds. The remaining parts of Figure 2 are representative of PDO/MCP-1 hybrids containing varying concentrations of MCP-1 as follows: (C) 3 ng/ml, (D) 30 ng/ml, (E) 300 ng/ml, and (F) 3000 ng/ml. There appear to be increasing numbers of cells present within the electrospun structures with increasing MCP-1 concentration.
Enzyme-Linked Immunosorbent Assay (ELISA) to Characterize MCP-1 Release from Electrospun PDO/MCP-1 Hybrid Scaffolds
Electrospun PDO scaffolds incorporated with MCP-1 were also examined for their potential to produce extended MCP-1 release. Over the course of 120 hours, MCP-1 released into supernatant peaked at 24 hours and was detectable by ELISA at levels as high as 23.5 pg/ml, but only when MCP-1 was added to PDO solutions at 3000 ng/ml prior to electrospinning (Figure 3) . At the highest electrospun MCP-1 concentration, released MCP-1 levels were Asterisks indicate statistically significant differences from control (0 ng/ml); *p < 0.05; **p < 0.01. statistically significantly greater than released MCP-1 from all other concentrations at all time points with the exception of the 72 hour measurement. There were no other statistically significant differences between test groups.
DISCUSSION
The aim in designing these PDO/MCP-1 electrospun hybrid structures was to incorporate approximately 100 ng MCP-1 per 6-mm diameter circular disc of material at the highest concentration utilized. Based upon the area of a 6-mm circular disc, the mandrel dimensions (1 cm  7.5 cm  0.5 cm), and assuming a uniform thickness of the electrospun material, the amount of MCP-1 required per ml of PDO was calculated to be 3000 ng. Accordingly, PDO/MCP-1 hybrids were fabricated containing MCP-1 at 3 ng/ml, 30 ng/ml, 300 ng/ml, and 3000 ng/ml in order to obtain theoretical MCP-1 concentrations of 0.1 ng/disc, 1.0 ng/disc, 10.0 ng/disc, and 100 ng/disc.
Following fabrication, it was first important to examine whether or not MCP-1 was indeed present in the electrospun structures, given that the chemokine was added to PDO/HFP solutions prior to electrospinning. The use of a test tube ELISA after overnight culture of these materials with macrophages allowed for the simultaneous determination of the presence or absence of MCP-1 and an indication of the biological activity of any MCP-1 present. Results of the test tube ELISA demonstrated a dose-responsive increase in macrophage adherence/infiltration with increasing MCP-1 concentration, indicating that MCP-1 was present in the structures and that it was biologically active. In order to determine whether the MCP-1 increased macrophage infiltration into the PDO scaffolds or whether the effect was an increased number of adherent cells on the scaffold surface, histological evaluations of samples from each group in this experiment were completed. arterial wall injury, however the upregulation was transient, with levels returning to baseline after 3 to 4 days [15] . By incorporating MCP-1 into electrospun scaffolds with the ability to deliver extended release, it may be possible to extend the time course over which MCP-1 is released during regeneration, potentially resulting in a greater cellular response, increased infiltration, and potentially increased vascular remodeling and angiogenesis. Over the course of 120 hours, MCP-1 released was detectable only for the highest concentration of incorporated MCP-1 (3000 ng/ml) and appeared to peak at 24 hours in culture. In this experiment, the media was not replaced for samples waiting to be collected at future time points, thus the potential degradation of released MCP-1 may have impacted these results. Although the degradation rate of MCP-1 has not been characterized, the relationship between a protein's half-life in vivo and its N-terminal amino acid is well documented [24, 25] . Because the residue at this location in the MCP-1 sequence is glutamine [26, 27] , the in vivo half-life of MCP-1 may be as little as 10 minutes. Recent work has demonstrated a hierarchy by which mammalian proteins are degraded, and although glutamine is a destabilizing amino acid, it requires two enzymatic conversions prior to the onset of degradation [25] , thus the halflife of MCP-1 in vivo may be somewhat longer than originally predicted. The in vitro half-life of MCP-1 (in cell-free, protease-free culture medium) remains unclear, however its half-life in vitro is likely to be larger than its half-life in vivo.
In order to eliminate any potential initial "burst" of MCP-1, materials were disinfected in ethanol and purged in sterile water prior to use in the release assay, however, it is possible that the initial burst was not completely eliminated. With some reasonable assumptions, we can estimate the percentage of MCP-1 released over the 120-hour release period. It is reasonable to assume 10% loss prior to and during electrospinning as a result of MCP-1 left behind in the scintillation vial and/or syringe and as a result of fibers not collected on the rectangular portion of the mandrel. To insure that the estimated MCP-1 in the structures is not over-estimated, a loss of 30% of the remaining MCP-1 is assumed to occur during the disinfection and purge, leaving 63% of the predicted MCP-1 concentration remaining in each disc. For the 100 ng/disc level, this equates to 63 ng MCP-1 per disc. A mean release at 24 hours of 23.54 pg/ml equates to 4.71 pg of MCP-1 released from the disc, or 0.007%. Kenawy et al. suggest that 120 hours is too short a time period to evaluate drug release from electrospun polymers having semi-crystalline structures and slow degradation rates [1] . PDO is a semi-crystalline polymer, and, as such, release of MCP-1 from the polymer fibers may be limited during the early stages of polymer degradation. The time course for this experiment was 120 hours, and it is likely that only a small percentage of MCP-1 was released during this time due to the semi-crystalline structure of PDO and its moderately slow degradation rate. Consequently, the diffusion of MCP-1 from the material is most likely limited during the 120 hour time period. While a longer time course seems logical in order to quantify the MCP-1 as the PDO begins to degrade, it will be difficult to measure total chemokine released due to the inevitable degradation of the chemokine over time.
In this preliminary work, we have demonstrated the ability to fabricate electrospun tissue regeneration templates combining a synthetic polymer and a biologically active chemokine. The resulting hybrid scaffolds were capable of increasing macrophage infiltration and adherence to the scaffolds, and they also demonstrated slow, sustained chemokine release over 120 hours at the high MCP-1 concentration. These results have significant implications for vascular tissue engineering and regenerative medicine applications. Further testing is underway in our laboratory in order to more fully evaluate and characterize these biomaterials, specifically with regard to the hypothesis that increased quantities and prolonged release of MCP-1 result in greater macrophage infiltration which itself may result in improved angiogenesis and tissue regeneration.
CONCLUSION
These preliminary experiments have demonstrated the ability to fabricate electrospun biomaterials containing a biologically active chemokine for use as a cellular homing device. Such materials may have the potential to improve in situ macrophage-based angiogenesis and tissue regeneration, and further investigation is warranted.
